Johannes Huebner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7770912/publications.pdf

Version: 2024-02-01

119	4,485	101543	123424
papers	citations	36 h-index	61 g-index

134	134	134	4973
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Opportunities for Antibiotic Stewardship Interventions in a Pediatric Hospital. Journal of Pediatric Infectious Diseases, 2022, 17, 083-089.	0.2	0
2	Epidemiological and genetic characteristics of vancomycin-resistant Enterococcus faecium isolates in a University Children's Hospital in Germany: 2019 to 2020. Antimicrobial Resistance and Infection Control, 2022, 11, 48.	4.1	5
3	Evaluating current practice and knowledge about antibiotic stewardship principles in paediatric tertiary hospitals to identify target areas for future teaching activities. Infection, 2022, , 1.	4.7	0
4	Cross-sectional seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to May 2021. Nature Communications, 2022, 13, .	12.8	16
5	Antimicrobial Use in Pediatric Oncology and Hematology: Protocol for a Multicenter Point-Prevalence Study With Qualitative Expert Panel Assessment. JMIR Research Protocols, 2022, 11, e35774.	1.0	3
6	SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 543-546.	1.3	11
7	Pediatric Antibiotic Stewardship. Pediatric Infectious Disease Journal, 2021, 40, 556-562.	2.0	6
8	Epitope Recognition of a Monoclonal Antibody Raised against a Synthetic Glycerol Phosphate Based Teichoic Acid. ACS Chemical Biology, 2021, 16, 1344-1349.	3.4	4
9	Weekly SARS-CoV-2 Sentinel Surveillance in Primary Schools, Kindergartens, and Nurseries, Germany, Juneâ€'November 2020. Emerging Infectious Diseases, 2021, 27, 2192-2196.	4.3	23
10	Feasibility and Diagnostic Accuracy of Saliva-Based SARS-CoV-2 Screening in Educational Settings and Children Aged <12 Years. Diagnostics, 2021, 11, 1797.	2.6	4
11	Generation of glucosylated sn-1-glycerolphosphate teichoic acids: glycerol stereochemistry affects synthesis and antibody interaction. RSC Chemical Biology, 2021, 2, 187-191.	4.1	4
12	Advances and Prospects in Vaccine Development against Enterococci. Cells, 2020, 9, 2397.	4.1	10
13	Synthetic Oligomers Mimicking Capsular Polysaccharide Diheteroglycan are Potential Vaccine Candidates against Encapsulated Enterococcal Infections. ACS Infectious Diseases, 2020, 6, 1816-1826.	3.8	12
14	Clinical and Epidemiological Features of a Family Cluster of Symptomatic and Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 362-365.	1.3	27
15	Comparison of antibiotic and acyclovir usage before and after the implementation of an on-site FilmArray meningitis/encephalitis panel in an academic tertiary pediatric hospital: a retrospective observational study. BMC Pediatrics, 2020, 20, 56.	1.7	25
16	Measures to maintain regular operations and prevent outbreaks of SARS-CoV-2 in childcare facilities or schools under pandemic conditions and co-circulation of other respiratory pathogens. GMS Hygiene and Infection Control, 2020, 15, Doc22.	0.3	11
17	Evaluation of the multiplex PCR based assay Unyvero implant and tissue infection application for pathogen and antibiotic resistance gene detection in children and neonates. Infection, 2019, 47, 195-200.	4.7	5
18	Conjugation of Different Immunogenic Enterococcal Vaccine Target Antigens Leads to Extended Strain Coverage. Journal of Infectious Diseases, 2019, 220, 1589-1598.	4.0	13

#	Article	IF	Citations
19	Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci. Infection and Immunity, 2019, 87, .	2.2	4
20	Clinical benefits of introducing real-time multiplex PCR for cerebrospinal fluid as routine diagnostic at a tertiary care pediatric center. Infection, 2019, 47, 51-58.	4.7	49
21	Streamlined Synthesis and Evaluation of Teichoic Acid Fragments. Chemistry - A European Journal, 2018, 24, 4014-4018.	3.3	18
22	Assessment of the multiplex PCR-based assay Unyvero pneumonia application for detection of bacterial pathogens and antibioticÂresistance genes in children and neonates. Infection, 2018, 46, 189-196.	4.7	33
23	Water flow paths are hotspots for the dissemination of antibiotic resistance in soil. Chemosphere, 2018, 193, 1198-1206.	8.2	27
24	Role of antimicrobial stewardship programmes in children: a systematic review. Journal of Hospital Infection, 2018, 99, 117-123.	2.9	66
25	Antibiotic use on paediatric inpatients in a teaching hospital in the Gambia, a retrospective study. Antimicrobial Resistance and Infection Control, 2018, 7, 82.	4.1	16
26	Deficits in knowledge, attitude, and practice towards blood culture sampling: results of a nationwide mixed-methods study among inpatient care physicians in Germany. Infection, 2017, 45, 433-441.	4.7	8
27	Pott's disease: a major issue for an unaccompanied refugee minor. Thorax, 2017, 72, 282-283.	5.6	5
28	Pediatric antibiotic stewardship: successful interventions to reduce broad-spectrum antibiotic use on general pediatric wards. Infection, 2017, 45, 493-504.	4.7	58
29	Knowledge, attitude and practice of Gambian health practitioners towards antibiotic prescribing and microbiological testing: a cross-sectional survey. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 117-124.	1.8	19
30	Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens. Journal of Infectious Diseases, 2017, 215, 1836-1845.	4.0	10
31	A retrospective analysis of paediatric inpatient data on antibiotic use in a teaching hospital in The Gambia. Gesundheitswesen, 2017, 79, .	0.5	0
32	The N-terminal domain of the thermo-regulated surface protein PrpA of Enterococcus faecium binds to fibrinogen, fibronectin and platelets. Scientific Reports, 2016, 5, 18255.	3.3	12
33	Deletion of fabN in Enterococcus faecalis results in unsaturated fatty acid auxotrophy and decreased release of inflammatory cytokines. Innate Immunity, 2016, 22, 284-293.	2.4	5
34	Genome-wide Screening Identifies Phosphotransferase System Permease BepA to Be Involved inEnterococcus faeciumEndocarditis and Biofilm Formation. Journal of Infectious Diseases, 2016, 214, 189-195.	4.0	36
35	Synthesis of E. faecium wall teichoic acid fragments. Bioorganic and Medicinal Chemistry, 2016, 24, 3893-3907.	3.0	16
36	Enterococcus faecalis Glycolipids Modulate Lipoprotein-Content of the Bacterial Cell Membrane and Host Immune Response. PLoS ONE, 2015, 10, e0132949.	2.5	8

#	Article	IF	Citations
37	Surface-Associated Lipoproteins Link Enterococcus faecalis Virulence to Colitogenic Activity in IL-10-Deficient Mice Independent of Their Expression Levels. PLoS Pathogens, 2015, 11, e1004911.	4.7	42
38	Phage-mediated Dispersal of Biofilm and Distribution of Bacterial Virulence Genes Is Induced by Quorum Sensing. PLoS Pathogens, 2015, 11, e1004653.	4.7	77
39	Distinct SagA from Hospital-Associated Clade A1 Enterococcus faecium Strains Contributes to Biofilm Formation. Applied and Environmental Microbiology, 2015, 81, 6873-6882.	3.1	35
40	A Vaccine Approach for the Prevention of Infections by Multidrug-resistant Enterococcus faecium. Journal of Biological Chemistry, 2015, 290, 19512-19526.	3.4	35
41	In vitro and in vivo activity of hyperimmune globulin preparations against multiresistant nosocomial pathogens. Infection, 2015, 43, 169-175.	4.7	27
42	Definitive Structural Assessment of Enterococcal Diheteroglycan. Chemistry - A European Journal, 2015, 21, 1749-1754.	3.3	26
43	Isolation of Highly Active Monoclonal Antibodies against Multiresistant Gram-Positive Bacteria. PLoS ONE, 2015, 10, e0118405.	2.5	12
44	Characterization of Two Metal Binding Lipoproteins as Vaccine Candidates for Enterococcal Infections. PLoS ONE, 2015, 10, e0136625.	2.5	25
45	Role of Glycolipids in the Pathogenesis of Enterococcus faecalis Urinary Tract Infection. PLoS ONE, 2014, 9, e96295.	2.5	11
46	A Novel Role for D-Alanylation of Lipoteichoic Acid of Enterococcus faecalis in Urinary Tract Infection. PLoS ONE, 2014, 9, e107827.	2.5	15
47	Synthetic Teichoic Acid Conjugate Vaccine against Nosocomial Gram-Positive Bacteria. PLoS ONE, 2014, 9, e110953.	2.5	33
48	Cystic Fibrosis Sputum DNA Has NETosis Characteristics and Neutrophil Extracellular Trap Release Is Regulated by Macrophage Migration-Inhibitory Factor. Journal of Innate Immunity, 2014, 6, 765-779.	3.8	170
49	Pyranosideâ€intoâ€Furanoside Rearrangement: New Reaction in Carbohydrate Chemistry and Its Application in Oligosaccharide Synthesis. Chemistry - A European Journal, 2014, 20, 16516-16522.	3.3	53
50	Detection of opsonic antibodies against Enterococcus faecalis cell wall carbohydrates in immune globulin preparations. Infection, 2014, 42, 749-755.	4.7	3
51	Wastewater Irrigation Increases the Abundance of Potentially Harmful Gammaproteobacteria in Soils in Mezquital Valley, Mexico. Applied and Environmental Microbiology, 2014, 80, 5282-5291.	3.1	80
52	Sa1752 Colitogenic Activity of Enterococcus Faecalis Requires Lipoprotein-Mediated Activation of Innate Immune Effector Functions in IL-10-/-Mice. Gastroenterology, 2014, 146, S-288.	1.3	0
53	The type IV secretion protein TraK from theEnterococcusconjugative plasmid pIP501 exhibits a novel fold. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 1124-1135.	2.5	9
54	Cell-Wall Glycolipid Mutations and Their Effects on Virulence of E. faecalis in a Rat Model of Infective Endocarditis. PLoS ONE, 2014, 9, e91863.	2.5	12

#	Article	IF	Citations
55	Identification of Peptidoglycan-Associated Proteins as Vaccine Candidates for Enterococcal Infections. PLoS ONE, 2014, 9, e111880.	2.5	34
56	Comparison of Enterococcus faecium and Enterococcus faecalis Strains Isolated from Water and Clinical Samples: Antimicrobial Susceptibility and Genetic Relationships. PLoS ONE, 2013, 8, e59491.	2.5	50
57	The 2.5 Ã... Structure of the Enterococcus Conjugation Protein TraM resembles VirB8 Type IV Secretion Proteins. Journal of Biological Chemistry, 2013, 288, 2018-2028.	3.4	50
58	Protection Against Staphylococcus aureus by Antibody to the Polyglycerolphosphate Backbone of Heterologous Lipoteichoic Acid. Journal of Infectious Diseases, 2012, 205, 1076-1085.	4.0	38
59	Natural Antibodies in Normal Human Serum Inhibit Staphylococcus aureus Capsular Polysaccharide Vaccine Efficacy. Clinical Infectious Diseases, 2012, 55, 1188-1197.	5.8	49
60	Secondary Cell Wall Polymers of Enterococcus faecalis Are Critical for Resistance to Complement Activation via Mannose-binding Lectin. Journal of Biological Chemistry, 2012, 287, 37769-37777.	3.4	37
61	Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin. BMC Research Notes, 2012, 5, 603.	1.4	15
62	Accumulation of Pharmaceuticals, Enterococcus, and Resistance Genes in Soils Irrigated with Wastewater for Zero to 100 Years in Central Mexico. PLoS ONE, 2012, 7, e45397.	2.5	108
63	Light fluorous synthesis of glucosylated glycerol teichoic acids. Carbohydrate Research, 2012, 356, 142-151.	2.3	16
64	The structure of the wall teichoic acid isolated from Enterococcus faecalis strain 12030. Carbohydrate Research, 2012, 354, 106-109.	2.3	17
65	Role of mprF1 and mprF2 in the Pathogenicity of Enterococcus faecalis. PLoS ONE, 2012, 7, e38458.	2.5	56
66	Automated solid phase synthesis of teichoic acids. Chemical Communications, 2011, 47, 8961.	4.1	17
67	Identification of SagA as a novel vaccine target for the prevention of Enterococcus faecium infections. Microbiology (United Kingdom), 2011, 157, 3429-3434.	1.8	28
68	Intra- and Interspecies Genomic Transfer of the Enterococcus faecalis Pathogenicity Island. PLoS ONE, 2011, 6, e16720.	2.5	54
69	Chemical structure of wall teichoic acid isolated from Enterococcus faecium strain U0317. Carbohydrate Research, 2011, 346, 2816-2819.	2.3	22
70	Deletion of the glycosyltransferase bgsB of Enterococcus faecalis leads to a complete loss of glycolipids from the cell membrane and to impaired biofilm formation. BMC Microbiology, 2011, 11, 67.	3.3	39
71	Serodiversity of Opsonic Antibodies against Enterococcus faecalis â€"Glycans of the Cell Wall Revisited. PLoS ONE, 2011, 6, e17839.	2.5	38
72	Large-Scale Screening of a Targeted Enterococcus faecalis Mutant Library Identifies Envelope Fitness Factors. PLoS ONE, 2011, 6, e29023.	2.5	46

#	Article	IF	Citations
73	Pathogenesis and immunity in enterococcal infections. Clinical Microbiology and Infection, 2010, 16, 533-540.	6.0	205
74	Enterococcal surface protein contributes to persistence in the host but is not a target of opsonic and protective antibodies in Enterococcus faecium infection. Journal of Medical Microbiology, 2010, 59, 1001-1004.	1.8	21
75	Prosthetic Valve Endocarditis due to Actinomyces neuii Successfully Treated with Antibiotic Therapy. Journal of Clinical Microbiology, 2010, 48, 1008-1011.	3.9	21
76	Screening of In Vivo Activated Genes in Enterococcus faecalis during Insect and Mouse Infections and Growth in Urine. PLoS ONE, 2010, 5, e11879.	2.5	33
77	Surface Protein EF3314 Contributes to Virulence Properties ofEnterococcus faecalis. International Journal of Artificial Organs, 2009, 32, 611-620.	1.4	18
78	Novel Interactions of Glycosaminoglycans and Bacterial Glycolipids Mediate Binding of Enterococci to Human Cells. Journal of Biological Chemistry, 2009, 284, 18194-18201.	3.4	48
79	Outcomes of Invasive Infection due to Vancomycin-Resistant Enterococcus faecium during a Recent Outbreak. Infection, 2009, 37, 540-543.	4.7	29
80	Glycolipids are involved in biofilm accumulation and prolonged bacteraemia in Enterococcus faecalis. Molecular Microbiology, 2009, 71, 1055-1069.	2.5	76
81	Glycolipids are involved in biofilm accumulation and prolonged bacteremia inEnterococcus faecalis. Molecular Microbiology, 2009, , .	2.5	9
82	Statistical epidemic modeling with hospital outbreak data. Statistics in Medicine, 2008, 27, 6522-6531.	1.6	17
83	Strong biofilm production, antibiotic multi-resistance and high gelE expression in epidemic clones of Enterococcus faecalis from orthopaedic implant infections. Biomaterials, 2008, 29, 580-586.	11.4	76
84	Environmental Contamination as an Important Route for the Transmission of the Hospital Pathogen VRE: Modeling and Prediction of Classical Interventions. Infectious Diseases: Research and Treatment, 2008, 1, IDRT.S809.	1.7	7
85	P1799 Antibodies against LTA isolated from E. faecalis 12030 recog-nize LTA from heterologous enterococcal strains but mediate opsonophagocytic killing only to CPS-A and CPS-B strains. International Journal of Antimicrobial Agents, 2007, 29, S512.	2.5	1
86	Cave Enterococcum!. International Journal of Artificial Organs, 2007, 30, 852-853.	1.4	3
87	The role of Enterococcus faecalis in orthopaedic peri-implant infections demonstrated by automated ribotyping and cluster analysis. Biomaterials, 2007, 28, 3987-3995.	11.4	23
88	Distribution of Four Capsular Serotypes of Enterococcus faecalis among Clinical Isolates from Different Geographical Origins and Infection Sites. Infection, 2006, 34, 22-25.	4.7	7
89	Enterococcal colonization of the gastro-intestinal tract: role of biofilm and environmental oligosaccharides. BMC Microbiology, 2006, 6, 60.	3.3	51
90	Immunochemical characterization of polysaccharide antigens from six clinical strains of Enterococci. BMC Microbiology, 2006, 6, 62.	3.3	7

#	Article	IF	Citations
91	Alanine Esters of Enterococcal Lipoteichoic Acid Play a Role in Biofilm Formation and Resistance to Antimicrobial Peptides. Infection and Immunity, 2006, 74, 4164-4171.	2.2	200
92	Opsonic Antibodies to Enterococcus faecalis Strain 12030 Are Directed against Lipoteichoic Acid. Infection and Immunity, 2006, 74, 5703-5712.	2.2	83
93	Analysis of the Specific Immune Response against Capsular Polysaccharides of Two Patients with Systemic Enterococcal Infections. Infection, 2005, 33, 373-376.	4.7	2
94	In vitro Assessment of the Host Response against Enterococcus faecalis Used in Probiotic Preparations. Infection, 2005, 33, 377-379.	4.7	10
95	Implant Infections Due to Enterococci: Role of Capsular Polysaccharides and Biofilm. International Journal of Artificial Organs, 2005, 28, 1079-1090.	1.4	27
96	Glycosaminoglycans Mediate Invasion and Survival ofEnterococcus faecalisinto Macrophages. Journal of Infectious Diseases, 2005, 191, 1253-1262.	4.0	45
97	Naturally Acquired Antibodies against Four Enterococcus faecalis Capsular Polysaccharides in Healthy Human Sera. Vaccine Journal, 2005, 12, 930-934.	3.1	23
98	A Putative Sugarâ€Binding Transcriptional Regulator in a Novel Gene Locus inEnterococcus faecalisContributes to Production of Biofilm and Prolonged Bacteremia in Mice. Journal of Infectious Diseases, 2004, 189, 420-430.	4.0	112
99	Serological and Genetic Diversity of Capsular Polysaccharides in Enterococcus faecalis. Journal of Clinical Microbiology, 2004, 42, 2548-2557.	3.9	58
100	Treatment and prevention of enterococcal infections â€“ alternative and experimental approaches. Expert Opinion on Biological Therapy, 2004, 4, 1519-1531.	3.1	19
101	Enterococcal infections: host response, therapeutic, and prophylactic possibilities. Vaccine, 2004, 22, 822-830.	3.8	126
102	Meeting summary. Vaccine, 2004, 22, 801-804.	3.8	1
103	Rationale for the development of immunotherapy regimens against enterococcal infections. Vaccine, 2004, 22, S31-S38.	3.8	21
104	Assessment of the role of antibiotics and enterococcal virulence factors in a mouse model of extraintestinal translocation. Critical Care Medicine, 2004, 32, 467-471.	0.9	23
105	Opsonophagocytic assay as a potentially useful tool for assessing safety of enterococcal preparations. International Journal of Food Microbiology, 2003, 88, 263-267.	4.7	18
106	Control of multiply resistant cocci: do international comparisons help?. Lancet Infectious Diseases, The, 2001, 1, 251-261.	9.1	81
107	Prophylactic and Therapeutic Efficacy of Antibodies to a Capsular Polysaccharide Shared among Vancomycin-Sensitive and -Resistant Enterococci. Infection and Immunity, 2000, 68, 4631-4636.	2.2	72
108	Structure of an antigenic teichoic acid shared by clinical isolates of Enterococcus faecalis and vancomycin-resistant Enterococcus faecium. Carbohydrate Research, 1999, 316, 155-160.	2.3	32

#	Article	IF	Citations
109	COAGULASE-NEGATIVE STAPHYLOCOCCI: Role as Pathogens. Annual Review of Medicine, 1999, 50, 223-236.	12.2	371
110	Isolation and Chemical Characterization of a Capsular Polysaccharide Antigen Shared by Clinical Isolates of Enterococcus faecalis and Vancomycin-Resistant Enterococcus faecium. Infection and Immunity, 1999, 67, 1213-1219.	2.2	127
111	Endemic Nosocomial Transmission of Staphylococcus epidermidis Bacteremia Isolates in a Neonatal Intensive Care Unit over 1O Years. Journal of Infectious Diseases, 1994, 169, 526-531.	4.0	115
112	Shigellemia in AIDS patients: Case report and review of the literature. Infection, 1993, 21, 122-124.	4.7	27
113	Exogenous or endogenous reservoirs of nosocomialPseudomonas aeruginosa andStaphylococcus aureus infections in a surgical intensive care unit. Intensive Care Medicine, 1993, 19, 161-165.	8.2	57
114	In vitro activity of vancomycin and teicoplanin againstStaphylococcus aureus andStaphylococcus epidermidis colonizing catheters. European Journal of Clinical Microbiology and Infectious Diseases, 1993, 12, 545-548.	2.9	27
115	Ribotyping of Pseudomonas aeruginosa Strains Isolated from Surgical Intensive Care Patients. Journal of Infectious Diseases, 1993, 167, 1216-1220.	4.0	50
116	In Vitro Activity of Sodium Bisulfite and Heparin against Staphylococci: New Strategies in the Treatment of Catheter-Related Infection. Journal of Infectious Diseases, 1993, 168, 235-237.	4.0	16
117	In vitro Susceptibility of Methicillin-Resistant Staphylococcus aureus and Slime-Producing and Non-Slime-Producing Coagulase-Negative Staphylococci to Fusidic Acid. Chemotherapy, 1992, 38, 206-210.	1.6	11
118	Influence of architectural design on nosocomial infections in intensive care units?a prospective 2-year analysis. Intensive Care Medicine, 1989, 15, 179-183.	8.2	33
119	Molecular Assessment of Staphylococcus Aureus Strains in STAT3 Hyper-IgE Syndrome Patients. Journal of Clinical Immunology, 0, , .	3.8	0